Patients with MYC-overexpressing DLBCL had poorer responses to selinexor than those without MYC overexpression, but no data regarding the clinical responses of this drug in patients with HGBCL-DH have been reported18. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.